N-methyl-N-boc-(2-hydroxypropyl)hydroxylamine | 1023955-67-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-methyl-N-boc-(2-hydroxypropyl)hydroxylamine
• 英文别名: tert-butyl N-(2-hydroxypropoxy)-N-methylcarbamate
• CAS: 1023955-67-0
• 化学式: C₉H₁₉NO₄
• 分子量: 205.254
• InChiKey: MTOZSIZPTKTNMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  丁二酸酐 、 N-methyl-N-boc-(2-hydroxypropyl)hydroxylamine 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以67%的产率得到2,2,5,8-tetramethyl-4,10-dioxo-3,6,9-trioxa-5-azatridecan-13-oic acid
  参考文献：
  名称：

  [EN] ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
  [FR] AUGMENTATION DE L'IMMUNOGÉNICITÉ DES ANTIGÈNES ASSOCIÉS AUX TUMEURS PAR L'ADJONCTION D'ÉPITOPES aGAL

  摘要：

  公开号：

  WO2008057235A3
• 作为产物：
  描述：

  N-羟基-N-甲基氨基甲酸叔丁酯 、 methyloxirane 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以39%的产率得到N-methyl-N-boc-(2-hydroxypropyl)hydroxylamine
  参考文献：
  名称：

  [EN] ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
  [FR] AUGMENTATION DE L'IMMUNOGÉNICITÉ DES ANTIGÈNES ASSOCIÉS AUX TUMEURS PAR L'ADJONCTION D'ÉPITOPES aGAL

  摘要：

  公开号：

  WO2008057235A3

文献信息

• Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
  申请人：Mautino Mario R.

  公开号：US20090060930A1

  公开（公告）日：2009-03-05

  The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

  本发明涉及用于选择性靶向和杀灭肿瘤细胞的方法和组合物。本发明描述了基于纯化的TAA蛋白或经化学、酶或化酶改变的TAA衍生合成肽的预防或治疗癌症疫苗，以引入αGal表位或αGal糖类似表位，以增强天然抗αGal抗体对抗原的包覆作用，刺激TAA的捕获和呈递，从而诱导针对肿瘤表达的TAA的体液和细胞免疫反应。动物的免疫系统因此被激发产生肿瘤特异性细胞毒性细胞和抗体，攻击和杀灭动物体内存在的肿瘤细胞。
• ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
  申请人：MAUTINO Mario R.

  公开号：US20120003251A1

  公开（公告）日：2012-01-05

  The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

  本发明涉及用于选择性靶向和杀死肿瘤细胞的方法和组合物。本发明描述了基于纯化的TAA蛋白或经化学、酶或化酶改变的TAA衍生合成肽的预防性或治疗性癌症疫苗，以引入αGal表位或αGal糖类模拟表位，从而通过天然抗-αGal抗体增强抗原的包被作用，促进TAA的捕获和呈递，从而诱导对肿瘤细胞表达的TAA的体液和细胞免疫反应。动物的免疫系统因此被刺激产生特异性的肿瘤细胞毒性细胞和抗体，这些细胞和抗体将攻击和杀死动物体内存在的肿瘤细胞。
• Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes
  申请人：Mautino Mario R.

  公开号：US08357777B2

  公开（公告）日：2013-01-22

  The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

  本发明涉及用于选择性靶向和杀死肿瘤细胞的方法和组合物。本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防性或治疗性癌症疫苗，通过化学、酶或化酶方法改变αGal表位或αGal糖类模拟表位，以增强天然抗αGal抗体对抗原的包覆作用，刺激TAA的捕获和呈递，从而诱导对肿瘤表达的TAA的体液和细胞免疫反应。动物的免疫系统因此被刺激产生肿瘤特异性细胞毒性细胞和抗体，攻击和杀死动物体内存在的肿瘤细胞。
• Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
  申请人：NewLink Genetics Corp.

  公开号：US08916169B2

  公开（公告）日：2014-12-23

  The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

  本发明涉及用于选择性靶向和杀死肿瘤细胞的方法和组合物。本发明描述了基于纯化的TAA蛋白或经化学、酶或化酶改变的TAA衍生的合成肽的预防性或治疗性癌症疫苗，以引入αGal表位或αGal类似表位，从而允许天然抗αGal抗体通过增强抗原的包覆作用来刺激TAA的捕获和呈递，从而诱导针对肿瘤表达的TAA的体液和细胞免疫反应。动物的免疫系统因此被刺激产生肿瘤特异性细胞毒性细胞和抗体，这些细胞和抗体将攻击和杀死动物体内存在的肿瘤细胞。
• US7998486B2
  申请人：——

  公开号：US7998486B2

  公开（公告）日：2011-08-16